ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor

blonca9
Jun 1
1 min read

She describes Bicara's data in HPV-negative HNSCC, and explains why the company is focused on this HVP-negative population specifically. Plus, how she believes the data compares to a closely watched competitor has a EGFR x LGR5 program.

Recent Posts

See All

AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight